The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs

Regul Pept. 2013 Feb 10:181:17-21. doi: 10.1016/j.regpep.2012.12.012. Epub 2013 Jan 11.

Abstract

The most striking sequence difference between glucagon-like peptide-1 (GLP-1)(2) and the longer-acting GLP-1 receptor agonist, exendin-4 (Ex-4),(3) is the nine-amino acid COOH-terminal extension of Ex-4. We investigated the contribution of this extension to the survival time of Ex-4. We assessed the overall metabolism of GLP-1, Ex-4, a COOH-terminally extended GLP-1 peptide (GLP-1+Ex(31-39); GLP-Ex),(4) and a COOH-terminally truncated exendin peptide (Ex(1-30)) in anaesthetized, catheterized pigs, with focus on the extraction across the kidneys and a peripheral tissue (a hindleg, representing muscle, adipose- and connective tissue). Peptide analysis was carried out with assays against the mid-region of the peptides, whereby the role of dipeptidyl peptidase-4 (DPP-4)(5) mediated NH(2)-terminal degradation could be disregarded. The half-life of GLP-1 was significantly increased when the COOH-terminal extension of Ex-4 was added (GLP-1 4.8±3.3min; GLP-Ex 19.5±3.3min). In contrast, there was no effect of truncating Ex-4 (Ex-4 32.4±4.1min; Ex(1-30) 28.4±1.7min). Ex-4 and Ex(1-30) were cleared solely by the kidneys at rates corresponding to the glomerular filtration rate (GFR),(6) while GLP-1 and GLP-Ex were cleared by both the kidneys and peripheral tissues. Both extraction rates were, however, significantly reduced with GLP-Ex compared to GLP-1. The renal clearance rate of GLP-1 greatly exceeded GFR, while GLP-Ex was cleared at a rate resembling GFR. In conclusion, the COOH-terminal extension of Ex-4 contributes minimally to the increased survival time of Ex-4, while addition of this sequence to GLP-1 significantly reduces its clearance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Amphibian Proteins / blood*
  • Amphibian Proteins / chemical synthesis
  • Amphibian Proteins / pharmacokinetics
  • Anesthesia
  • Animals
  • Dipeptidyl Peptidase 4 / blood
  • Exenatide
  • Female
  • Glomerular Filtration Rate
  • Glucagon-Like Peptide 1 / blood*
  • Glucagon-Like Peptide 1 / chemical synthesis
  • Glucagon-Like Peptide 1 / pharmacokinetics
  • Half-Life
  • Hypoglycemic Agents / blood*
  • Hypoglycemic Agents / chemical synthesis
  • Hypoglycemic Agents / pharmacokinetics
  • Lizards
  • Molecular Sequence Data
  • Peptide Fragments / blood*
  • Peptide Fragments / chemical synthesis
  • Peptide Fragments / pharmacokinetics
  • Peptides / blood*
  • Peptides / chemical synthesis
  • Peptides / pharmacokinetics
  • Protein Stability
  • Proteolysis
  • Structure-Activity Relationship
  • Swine
  • Venoms / blood*
  • Venoms / chemical synthesis
  • Venoms / pharmacokinetics

Substances

  • Amphibian Proteins
  • Hypoglycemic Agents
  • Peptide Fragments
  • Peptides
  • Venoms
  • Glucagon-Like Peptide 1
  • Exenatide
  • Dipeptidyl Peptidase 4